import Head from "next/head";
import Image from "next/image";
import { Navbar } from "../components/header";
import { Footer } from "../components/footer";
import { People } from "../components/people";
import Pipelines from "../components/Pipeline";

export default function Home() {
  const sectionWrapperClasses = "py-6";

  const linkStyling = "text-blue-600 hover:text-yellow-700 underline focus:outline-none focus:ring-2 focus:ring-gray-400 rounded";

  return (
    <div>
      <Head>
        <title>Anwita Biosciences Inc.</title>
        <link rel="icon" href="/favicon.ico" />
        <meta name="description" content="Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases." />
        <meta name="keywords" content="Anwita, Bioscience, Anwita Bioscience, Anwita Bio" />
      </Head>

      <Navbar />

      <main>
        <div id='banner-wrapper' className='bg-home-banner bg-cover bg-center flex content-center justify-center h-[300px] lg:h-[400px]'>
          <div
            className='flex flex-col w-full flex-none text-center content-center justify-center items-center space-y-2' style={{ backgroundColor: "rgba(54, 58, 69, 0.4)" }}
          >
            <h1 className='text-4xl sm:text-6xl lg:text-8xl text-white font-bold' style={{ textShadow: "4px 4px rgba(0,0,0, 0.8)" }}>Anwita Biosciences</h1>
          </div>
        </div>

        <div id='primary-content-wrapper' className='py-2 mx-auto text-blue-900' style={{ width: "1200px", maxWidth: "80vw" }}>

          <div className={sectionWrapperClasses}>
            <span id='about' className='anchor'/>
            <h1 className='text-center text-4xl mb-4 font-semibold'>Our Mission</h1>
            <div className='flex flex-col'>
              <div className='place-self-center'>
                <p className='text-xl max-w-prose mb-6'>
                    Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies.
                </p>
                <p className='text-xl max-w-prose mb-6'>
                    Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.
                </p>
              </div>
            </div>
          </div>

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <div className={sectionWrapperClasses + " flex flex-col items-start"}>
            <span id='science' className='anchor'/>
            <h1 className='text-center text-4xl mb-6 font-semibold place-self-center'>Science</h1>
            <div className="flex flex-col place-self-center">
              <div className='w-full place-self-center' style={{ maxWidth: "55rem" }}>
                <Image src='/assets/graphics/anwitaTech.webp'
                  width='1620' height = '862' alt='A diagram showcasing Anwita&apos;s technology workflow.' />
              </div>

              <p className='text-xl my-4 max-w-[75ch] place-self-center'>
              Anwitaâ€™s core technology integrates structure-guided AccuKine<sup>TM</sup> cytokine evolution and AccuBody<sup>TM</sup> discovery of full spectrum nanobodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile and great developmentability. Our unique product portfolio includes half-live extended Exenokines, immune cell- or tumor cell-targeting Mableukines, and bi-functional Duoleukins. These new generation of cytokines could serve as powerful novel immune therapies with a wide range of applications in treating patients with cancers and autoimmune diseases.
              </p>

            </div>
          </div>

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <div className={sectionWrapperClasses}>
            <span id='pipeline' className='anchor'/>
            <h1 className='text-center text-4xl mb-4 font-semibold'>Pipeline</h1>
            <Pipelines
              pipelines={[
                // Progress will be rounded to the nearest multiple of 5
                {
                  name: "Exenokine&#8203;-21",
                  description: "JS014 is an Exenokine-21 molecule being developed as an IV infusion treatment for cancer patients, either alone or in combination with immune checkpoint inhibitors. The antitumor activities of JS014 have been demonstrated in multiple mouse tumor models, both as a superior single agent when compared to the unmodified rhIL-21 and as an effective combined agent potentiating the efficacy of immunotherapies. JS014 has recently received IND acceptance from the US FDA and China NMPA. Anwita plans to conduct a first-in-human Phase 1 clinical trial to evaluate the safety and efficacy of JS14 in cancer patients in Q1 2022. JS014 is partnered with Shanghai Junshi Biosciences for the Greater China territories.",
                  target: "IL-21",
                  indication: "Solid Tumors",
                  progress: 80,
                  partnership: "top-alliance",
                },
                {
                  name: "Exenokine&#8203;-2",
                  description: "RT003 is a systemically delivered Exenokine-2 molecule being developed to minimize the toxicity observed with recombinant IL-2 therapy while maximizing the clinical benefit as a monotherapy or in combination with immune checkpoint inhibitors in multiple tumor types. Key features of RT003 include preferential activation of the &beta;&gamma;-IL-2 receptor and extension of half-life for an improved systemic exposure. In preclinical studies, RT003 exhibits potent antitumor and PD activities with a favorable pharmacokinetic and tolerability profile. Pharmacological activity of RT003 is driven by the selective activation and expansion of effector T cells. RT003 is partnered with Shanghai Junshi Biosciences for the Greater China territories.",
                  target: "IL-2",
                  indication: "Solid Tumors",
                  progress: 60,
                  partnership: "top-alliance",
                },
                {
                  name: "Mableukin&#8203;-2PD1",
                  description: "Mableukine-2PD1 is a targeted fusion protein comprised of an anti-PD1 antibody and an optimized IL-2. The IL-2 component is engineered to have significantly lower toxicity. The anti-PD1 antibody component of the fusion protein serves not only to block the interaction between PD1 and PD-L1 but also functions to direct the optimized IL-2 to the desired cell populations within the tumor microenvironment. Leveraging on the function of PD1 and IL-2 signaling pathway to selectively stimulate effector T cells, Mableukine-2PD1 exhibits excellent antitumor and pharmacodynamic activities with low systematic toxicities.",
                  target: "PD-1 and IL-2",
                  indication: "Solid Tumors",
                  progress: 55,
                },
                {
                  name: "MSLN&#8203;-MMAE",
                  description: "MSLN-MMAE is a novel mesothelin (MSLN)-directed antibody-drug conjugate (ADC) composed of a humanized anti-MSLN monoclonal antibody coupled to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE). Specific binding to tumor cells that overexpress MSLN, MSLN-MMAE induced cell death in vitro in a dose-dependent manner and significantly inhibited the growth of several target-expressing xenograft tumor models. Anwita plans to further develop our lead molecule for the treatment of patients with MSLN-expressing tumors such as mesotheliomas, pancreatic, and ovarian cancers.",
                  target: "Meso&shy;thelin",
                  indication: "Solid Tumors",
                  progress: 40,
                },
                {
                  name: "B7H3&#8203;-MMAE",
                  description: "B7H3-MMAE, an antibody-drug conjugate (ADC) targeting the human B7H3 protein, is comprised of monomethyl auristatin E (MMAE) conjugated to a humanized anti-B7H3 antibody. In vitro, B7H3-MMAE exhibits cytotoxicity towards B7H3-positive human tumor cell lines. In vivo, B7H3-MMAE demonstrates potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer. These studies provide evidence of a potentially favorable therapeutic index and support the development of B7H3-MMAE for the treatment of solid cancers.",
                  target: "B7H3",
                  indication: "Solid Tumors",
                  progress: 40,
                },
                {
                  name: "AWT&#8203;-024",
                  description: "IL-36 cytokines and their receptors are normally expressed at low levels but are markedly elevated during inflammation in several tissues including skin, lung, joints, and gut. The importance of proper IL-36 signaling has been demonstrated in several preclinical in vivo models of skin inflammation, lung inflammation, and inflammatory bowel disease. In the human setting, based on proof-of-concept clinical data, blockade of IL-36 signaling through inhibition of IL-36R could be an appealing therapeutic target for patients suffering from chronic and potentially life-threatening generalized pustular psoriasis. Anwita is developing a best-in-class IL-36R directed antibody-based therapeutic that exhibits exquisite potency and excellent developmentability profile.",
                  target: "IL-36 Receptor",
                  indication: "Autoimmune",
                  progress: 40,
                },
                {
                  name: "Discovery Programs",
                  description: "Anwita applies our AccuKine^TM^ cytokine evolution and AccuBody^TM^ discovery platform to design, optimize, and validate new therapeutic candidates with improved pharmaceutical properties in immuno-oncology, autoimmune, and inflammatory disease areas.",
                  progress: 20,
                },
              ]}
            />
            <p className="text-sm my-4">Click or tap on any Program to read more about that project.</p>
          </div>

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <People sectionWrapperClasses={sectionWrapperClasses} />

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <div className={sectionWrapperClasses}>
            <span id='news' className='anchor'/>
            <h1 className='text-center text-4xl mb-6 font-semibold'>News</h1>
            <div className='text-xl grid md:grid-cols-2 xl:grid-cols-3 gap-4'>
              {/* TODO: Refactor into actual React components */}
              <div className='flex flex-col bg-gray-100 p-8 rounded-lg'>
                <p className='mb-4'><b>Date:</b> October 29<sup>th</sup>, 2021</p>
                <p className='mb-4'>Anwita Biosciences, Inc. Announces Initiation of first-in-human Phase 1 clinical trial of Exenokine-21 for monotherapy and combination, earns $2.5 million milestone for IND acceptance from Partner Shanghai Junshi Biosciences</p>
                <p className="mt-auto"><b><a className={linkStyling} target='_blank' href='/assets/news/Press release Exenokine-21 IND.pdf'>Press Release</a></b></p>
              </div>
              <div className='flex flex-col bg-gray-100 p-8 rounded-lg'>
                <p className='mb-4'><b>Date:</b> June 28<sup>th</sup>, 2021</p>
                <p className='mb-4'>Anwita Biosciences, Inc. Completes $18.5 Million Series B Financing to Advance Its Improved Cytokines (Exenokines) And Tumor Targeting Antibody Drug Conjugates</p>
                <p className="mt-auto"><b><a className={linkStyling} target='_blank' href='/assets/news/Press release 2021-07-13 V2-20211207.pdf'>Press Release</a></b></p>
              </div>
              <div className='flex flex-col bg-gray-100 p-8 rounded-lg'>
                <p className='mb-4'><b>Date:</b> September 30<sup>th</sup>, 2020</p>
                <p className='mb-4'>Anwita Biosciences and Shanghai Junshi Biosciences entered into a new collaboration in which Junshi was granted the exclusive rights to Anwita&apos;s Exenokine-2, an improved IL-2 variant with extended half-life, in the Greater China territories.</p>
                <p className="mt-auto"><b><a className={linkStyling} target='_blank' href='/assets/news/Anwita-Junshi IL-2 Collaboration HK Announcement.pdf'>Press Release</a></b></p>
              </div>
              <div className='flex flex-col bg-gray-100 p-8 rounded-lg'>
                <p className='mb-4'><b>Date:</b> June 24<sup>th</sup>, 2019</p>
                <p className='mb-4'>Strategic collaboration between Anwita Biosciences and Shanghai Junshi Biosciences whereby Junshi was granted the exclusive rights to develop and commercialize Anwita&apos;s Exenokine-21 program in the Greater China territories.</p>
                <p className="mt-auto"><b><a className={linkStyling} target='_blank' href='/assets/news/Anwita-Junshi First Collaboration (IL-21, HK Announcement).pdf'>Press Release</a></b></p>
              </div>
            </div>
          </div>

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <div className={sectionWrapperClasses}>
            <span id='careers' className='anchor'/>
            <h1 className='text-center text-4xl my-2 font-semibold'>Careers</h1>
            <hr className='mt-3 h-px border-1 border-gray-400 w-1/3 m-auto'></hr>
            <div className="lg:grid grid-cols-left-uneven gap-2">
              <div className="my-4">
                <h2 className='text-3xl my-4 italic font-semibold text-center'>Working at Anwita</h2>
                <p className='text-xl'>We are always seeking exceptional talent that is passionate about making a difference in the lives of patients with cancer or autoimmune disorders. If you share our mission, and are interested in joining our team, please reach out to us via email at <a href='mailto:contact@anwitabio.com' className={linkStyling}>contact@anwitabio.com</a>.</p>
              </div>
              <div className="my-4">
                <h2 className='text-center text-3xl my-4 italic font-semibold'>Benefits</h2>
                <div className='text-xl px-4 lg:px-8'>
                  <ul className='list-disc list-inside'>
                    <li>Competitive compensation</li>
                    <li>Stock options at all levels</li>
                    <li>401(K) plan</li>
                    <li>Official holidays</li>
                    <li>Generous paid time off (PTO)</li>
                    <li>Sick days</li>
                    <li>Medical plan</li>
                    <li>Dental plan</li>
                    <li>Visional plan</li>
                    <li>Life insurance</li>
                  </ul>
                </div>
              </div>
            </div>
          </div>

          <hr className='my-3 h-px border-1 border-gray-400'></hr>

          <div className={sectionWrapperClasses}>
            <span id='contact' className='anchor'/>
            <h1 className='text-center text-4xl mb-6 font-semibold'>Contact</h1>
            <div className='flex flex-col sm:flex-row content-evenly justify-center gap-8'>
              {/* <iframe className="w-96 h-48" src="https://www.google.com/maps/embed?pb=!1m18!1m12!1m3!1d1669.5229423824994!2d-122.26270389781278!3d37.51492603078649!2m3!1f0!2f0!3f0!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x808f98aa79bc4f55%3A0xd47219d8b27ce42a!2sAnwita%20Biosciences!5e0!3m2!1sen!2sus!4v1632246025164!5m2!1sen!2sus" style={{width: "35rem", height: "30rem", maxWidth: "95%", maxHeight: "35rem", border: 0}} allow="fullscreen" allowFullScreen={true} loading="lazy"></iframe> */}
              <div className='sm:text-right'>
                <p>Company Address: <br/><a href='https://www.google.com/maps/place/300+Industrial+Rd,+San+Carlos,+CA+94070/@37.5149181,-122.2641003,17z/data=!3m1!4b1!4m5!3m4!1s0x808f98aa79063b39:0x9744f7cb0ddf62fa!8m2!3d37.5149181!4d-122.2619063' target="_blank" rel="noreferrer noopener" className={linkStyling}>300 Industrial Road,<br/>San Carlos, CA 94070</a></p>
                <p>Phone:&nbsp;<a href='tel:1-650-600-9828' target='_blank' className={linkStyling} rel="noreferrer">(650) 600-9828</a></p>
                <p>Email:&nbsp;<a href='mailto:contact@anwitabio.com' className={linkStyling}>contact@anwitabio.com</a></p>
              </div>
              <div>
                <p>Shanghai Division: <br/><a href='https://www.google.com/maps/place/China,+Shang+Hai+Shi,+Pu+Dong+Xin+Qu,+%E7%A7%80%E6%B5%A6%E8%B7%AF2555%E5%8F%B7/@31.1302446,121.6053713,17z/data=!3m1!4b1!4m5!3m4!1s0x35b2788b3666b481:0x462a91e8462cbf6d!8m2!3d31.13024!4d121.60756' target="_blank" rel="noreferrer noopener" className={linkStyling}>11/F Building E6,<br/>2555 Xiupu Road<br/>Pudong New Area, Shanghai</a></p>
                <p>Phone:&nbsp;<a href='tel:86-21-58080598' target='_blank' className={linkStyling} rel="noreferrer">86(21)-58080598</a></p>
              </div>
            </div>
          </div>
        </div>
      </main>

      <footer>
        <Footer />
      </footer>

    </div>
  );
}
